Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.42 |
| ▸ | DPP4 known ✓ | P27487 | 3/20 | 0.35 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 5/20 | 0.33 |
| ▸ | TPSD1 | Q9BZJ3 | 5/20 | 0.33 |
| ▸ | TPSG1 | Q9NRR2 | 5/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5285959 | 1.00 | CYP19A1 (0.42) | CYP19A1EPHX1DPP4DPP7NAAA | |
| Hydrochloric Acid SCHEMBL18492024 | 1.00 | CYP19A1 (0.42) | CYP19A1EPHX1DPP4DPP7NAAA | |
| SCHEMBL18378683 | 0.98 | CYP19A1 (0.44) | CYP19A1EPHX1DPP4DPP7NAAA | |
| SCHEMBL15574877 | 0.98 | CYP19A1 (0.44) | CYP19A1EPHX1DPP4DPP7NAAA | |
| SCHEMBL158169 | 0.98 | CYP19A1 (0.44) | CYP19A1EPHX1DPP4DPP7NAAA | |
| Hydrochloric Acid SCHEMBL217045 | 0.96 | CYP19A1 (0.46) | CYP19A1EPHX1NAAAL3MBTL1CYP3A4 | |
| Hydrochloric Acid SCHEMBL5281324 | 0.96 | CYP19A1 (0.46) | CYP19A1EPHX1NAAAL3MBTL1CYP3A4 | |
| Hydrochloric Acid SCHEMBL20586240 | 0.96 | CYP19A1 (0.46) | CYP19A1EPHX1NAAAL3MBTL1CYP3A4 | |
| Hydrochloric Acid SCHEMBL28854935 | 0.94 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1CYP3A4 | |
| Hydrochloric Acid SCHEMBL28854937 | 0.94 | CYP19A1 (0.49) | CYP19A1EPHX1NAAAL3MBTL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260015373-A1 | STAT6 MODULATORS AND USES THEREOF | RECLUDIX PHARMA INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4617278-A1 | NUCLEOTIDE ANALOG, AND COMPOSITION AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| CN-115135383-B | Antiviral compounds | 吉利德科学公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11939347-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-3334743-B1 | ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-110382514-B | Prodrugs of HCV NS5B polymerase inhibitors and methods of making and using the same | 亚历山大·瓦西里耶维奇·伊瓦切恩科 | 2023-06-02 | — | — | CN | disclosed |
| EP-4172160-A2 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2007002912-A2 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002808-A1 | ANTI-NONMELANOMA CARCINOMA COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1716162-A1 | PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES | GILEAD SCIENCES, INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060046981-A1 | Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. | 2006-03-02 | — | — | US | disclosed |
| US-20060030545-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050222090-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. | 2005-10-06 | — | — | US | disclosed |
| WO-2005066189-A1 | PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES | GILEAD SCIENCES, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222090-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | CCNY, CCNO, CCNB3 | CYP19A1 711/4885DPP4 4295/4885CHRM2 345/4885 |
| US-20060046981-A1 | Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof | HCCS, RCOR3, MSRB3 | CYP19A1 482/4885DPP4 4361/4885CHRM2 94/4885 |
| US-20260015373-A1 | STAT6 MODULATORS AND USES THEREOF | STAT6, STAT5A, STAT3 | CYP19A1 4440/4885DPP4 2593/4885CHRM2 622/4885 |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | CYP19A1 626/4885DPP4 4317/4885CHRM2 310/4885 |
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | TYMP, PNP, DUT | CYP19A1 4201/4885DPP4 657/4885CHRM2 4074/4885 |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | CYP19A1 4345/4885DPP4 539/4885CHRM2 4274/4885 |
| US-11939347-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | CYP19A1 4345/4885DPP4 539/4885CHRM2 4274/4885 |
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | PNP, SLC28A1, SLC29A1 | CYP19A1 3972/4885DPP4 355/4885CHRM2 1826/4885 |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | CYP19A1 626/4885DPP4 4317/4885CHRM2 310/4885 |
| US-20060030545-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | CCNY, CCNO, CCNB3 | CYP19A1 621/4885DPP4 4175/4885CHRM2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.